FDA reportedly eyeing staff bonuses to accelerate drug reviews
Source: SeekingAlpha
2026-02-26 13:35:52 ET
More on leading drugmakers
- Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
- Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)
- Merck: Why Investors Should Remain Bullish Despite Patent Risks
- Kenvue effort to dismiss Tylenol case rejected by Texas judge
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Read the full article on Seeking Alpha
For further details see:
FDA reportedly eyeing staff bonuses to accelerate drug reviews
Bristol-Myers Squibb Company
NASDAQ: BMY
BMY Trading
0.36% G/L:
$59.35 Last:
3,245,443 Volume:
$59.49 Open:
BMY Latest News
March 09, 2026 06:59:00 am
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
BMY Stock Data
$123,325,918,376
2,034,328,000
N/A
1394
N/A
Pharmaceuticals
Healthcare
US
Princeton
